InsidersTradesSigma
Total declarations
Companies
▲ Purchases (13 ops.)
▼ Sales (2 ops.)
Insider track record
Board DirectorDisclosed buys
13
Disclosed sells
2
T+90 hit rate
56%
T+90 mean return
-2.7%
Across 9 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the complete record of transactions filed by Johnson David Michael, Director. Officer active across 2 companies, notably Zentalis Pharmaceuticals, Inc.. Cumulatively, 26 disclosures have been logged. Breakdown: 13 buys · 2 sells. Total volume traded: €2.2m. History available since 4 June 2021. The latest transaction was filed on 16 May 2025 (Acquisition). Regulator: SEC (Form 4). The full history is accessible without signup.
Declarations26 total
15,000 sharesCommon StockSEC:0001193125-26-271168:0
20,000 shares@ US$4.906.0% of flowCommon StockSEC:0000950170-25-075412:0
Ideal exit: 10 Feb 2026 (T+270)
10,500 shares0Common StockSEC:0000950170-24-076707:0
48,429 shares0Common StockSEC:0001725160-24-000141:0
17,000 shares@ US$9.87922.1% of flowCommon StockSEC:0001725160-23-000201:0
Ideal exit: 6 Aug 2024 (T+270)
76,000 shares@ US$7.1734.7% of flowCommon StockSEC:0000950170-23-062214:0
Ideal exit: 3 Aug 2024 (T+270)
13,500 shares@ US$8.27137.3% of flowCommon StockSEC:0000950170-23-052244:0
Ideal exit: 29 Jun 2024 (T+270)
19,059 shares0Common StockSEC:0001725160-23-000146:0
300 shares@ US$10.000.2% of flowCommon StockSEC:0000899243-23-001324:0
Ideal exit: 2 Oct 2023 (T+270)
2,000 shares@ US$9.751.3% of flowCommon StockSEC:0000899243-22-039594:0
Ideal exit: 24 Sept 2023 (T+270)
5,000 shares@ US$12.374.0% of flowCommon StockSEC:0000899243-22-038695:0
Ideal exit: 28 Aug 2023 (T+270)
3,000 shares@ US$15.040.0050% mcap100.0% of flowCommon StockSEC:0000899243-22-022456:0
Ideal exit: 7 Mar 2023 (T+270)
3,000 shares@ US$15.042.9% of flowCommon StockSEC:0000899243-22-022456:1
Ideal exit: 7 Mar 2023 (T+270)
10,000 shares@ US$15.049.7% of flowCommon StockSEC:0000899243-22-022456:2
Ideal exit: 7 Mar 2023 (T+270)
7,000 shares@ US$13.996.4% of flowCommon StockSEC:0000899243-22-022456:3
Ideal exit: 10 Mar 2023 (T+270)
7,000 shares@ US$13.996.4% of flowCommon StockSEC:0000899243-22-022456:4
Ideal exit: 10 Mar 2023 (T+270)
20,000 shares@ US$13.9918.3% of flowCommon StockSEC:0000899243-22-022456:5
Ideal exit: 10 Mar 2023 (T+270)
24,871 shares0Common StockSEC:0001725160-22-000121:0
7,500 shares0Common StockSEC:0001725160-21-000242
7,500 shares0Common StockSEC:0001725160-21-000242:0
139,672 shares0Common StockSEC:0000899243-21-042361:0
139,672 shares0Common StockSEC:0000899243-21-042361
4,892 shares@ US$65.95010.096% mcap50.0% of flowCommon StockSEC:0001725160-21-000197:0
4,892 shares@ US$65.950139.0% of flowCommon StockSEC:0001725160-21-000197
5,000 shares0Common StockSEC:0001725160-21-000142:0
25 of 26 declarations
About Johnson David Michael
David Michael Johnson serves as a Director at Zentalis Pharmaceuticals, Inc. and Aura Biosciences, Inc. In these roles, he participates in corporate governance and strategic decision-making. Johnson leverages his expertise to help define the strategic directions of the companies, ensuring they comply with regulatory requirements and achieve their objectives.
